Mechanism of Antivirals Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

Why do we need antivirals?

A
  • Needed for quick killing infections- flu, Ebola, MERS, SARS.
  • Needed for slow, progressive chronic disease, leading to cancer- hepatitis B/C and hpv.
  • For HIV to prevent AIDS.
  • For acute inflammatory viruses- herpes.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the 5 uses of antivirals?

A
  1. Treatment of acute infection
    a. Influenza; Chickenpox; herpes infections -(aciclovir)
  2. Treatment of chronic infection:
    a. HCV, HBV, HIV (numerous different agents)
  3. Post-exposure prophylaxis and preventing infection:
    a. HIV (PEP)
  4. Pre-exposure prophylaxis:
    a. HIV (PrEP)
  5. Prophylaxis for reactivated infection: e.g. in transplantation
    a. CMV (ganciclovir, foscarnet)
    b. To prevent viruses being reactivated
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What does selective toxicity mean?

A
  • Selective Toxicity - when a drug has an effect against one component but not another
  • Due to the differences in structure and metabolic pathways between host and pathogen
  • Harm microorganisms, not the host
  • Target in microbe, not host (if possible)
  • Difficult for viruses (intracellular), fungi and parasites
  • Variation between microbes
  • It has to have a very minimal on the host
  • The target should be specific in the antigen but this is difficult as viruses require the host cell
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Why is it so difficult to develop effective, non-toxic anti-viral drugs ?

A
  • Viruses enter cells using cellular receptors which may have other functions
  • Viruses must replicate inside cells – obligate intracellular parasites
  • Viruses take over the host cell replicative machinery
  • Virsues have high mutation rate - quasispecies
  • Anti-virals must be selective in their toxicity
  • i.e. exert their action only on infected cells
  • Some viruses are able to remain in a latent state e.g. herpes, HPV
  • Some viruses are able to integrate their genetic material into host cells. Therefore it is impossible to remove this integrated virus e.g. HIV
  • If you block a receptor, it could have some toxic effects.
  • Viruses can escape anti-viral drugs as they can have lots of mutations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What should we consider when developing antivirals?

A
  • Can stages of infection be targeted?
  • Cellular receptor may have other important function
  • Viral enzymes may be very similar to host
  • Blocking cellular enzyme may kill cell
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe the life cycle of a virus

A
  • Virus attaches to a membrane and then goes in via endocytosis or fusion
  • It has to uncoat and release its genome
  • It also has to make mRNA which goes on to the ribosomes in the cell where is starts to make viral proteins.
  • The virus will then reassemble and can escape through cell lysis.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the various modes of action of antivirals

A
  1. Preventing virus adsorption onto host cell
  2. Preventing penetration
  3. Preventing viral nucleic acid replication (nucleoside analogues)
  4. Preventing maturation of virus
  5. Preventing virus release
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the 4 families of herpes virus and what can they be treated with?

A

Acyclovir- IV/oral/topical for HSV, VZV treatment/prophylaxis.

Ganciclovir- IV/oral for CMV/EBV prophylaxis

Foscarnet- IV/local application for CMV

Cidofovir- IV for CM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How does aciclovir work?

A
•	Aciclovir is activated to active drug 
•	Substantially more in infected cells
•	Requires 2 viral enzymes 
o	Selectively activate ACV 
o	Selectively inhibited 
•	Accounts for low toxicity
  • It is an analogue of GTP
  • It doesn’t have a 3’ hydroxyl
  • It will insert in the DNA and prevent it from polymerising
  • It needs to be activated first
  • It is phosphorylated first by a viral thymidine kinase
  • It then remains stable and gets di,tri, phosphorylated by cellular kinases
  • It is only active when it is tri phos…
  • It is now an inhibitor for viral DNA polymerase
  • It will compete from GTP and will stop the virus from making the viral genome
  • It will only be phosphaylated in the presence of a virus as it needs a viral thymidine kinase
  1. GTP analogue acts on viral thymidine kinase.
  2. Activated to activated drug.
  3. Competitive inhibitor to HSV DNA pol.
  4. Requires 2 viral enzymes- selectively activated by HSV TK and selectively inhibited.
  5. Low toxicity as found substantially more in active form in cells with these enzymes- i.e. infected cells.
  6. HSV (herpes) thymidine kinase (TK) has 100x more affinity to ACV than cellular phosphokinases.
  7. Acyclovir triphosphate has 30x more affinity for HSV DNA pol compared to cellular DNA pol.
  8. Also, highly polar so difficulty leaving and entering cells but easily taken in before phosphorylation.
  9. Also, there is a DNA chain terminator.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Why is aciclovir so effective and safe?

A
  • HSV thymidine kinase (TK) has 100x the affinity for ACV compared with cellular phosphokinases
  • Aciclovir triphosphate has 30x the affinity for HSV DNA polymerase compared with cellular DNA polymerase
  • Aciclovir triphosphate is a highly polar compound - difficult to leave or enter cells (but aciclovir is easily taken into cells prior to phosphorylation)
  • DNA chain terminator
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How does Ganciclovir work?

How is it activated?

What does it treat and what does it target?

A
  1. Active for CMV (cytomegalovirus). Reactivated infection or prophylaxis in organ transplant recipients.
  2. For congenital infection in newborns and retinitis in immunosuppressed.
  3. Structurally similar to acyclovir.
  4. CMV does not encode TK but has UL97 kinase.
  5. Inhibits CMV DNA polymerase.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How does FOSCARNET work?

What does it do?

What infection does it target?

A

• Selectively inhibits viral DNA/RNA polymerases and RTs
• No reactivation required
• Binds pyrophosphate binding site – a structural mimic
• Used for CMV infection in the immunocompromised
o e.g. pneumonia in solid organ and bone marrow transplants.
• May be used because of ganciclovir resistance (TK mutants)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How does CIDOFOVIR work?

A
  • Chain terminator - targets DNA polymerase
  • Competes with dCTP
  • Monophosphate nucleotide analog
  • Prodrug – phosphorylated by cellular kinases to di-phosphate
  • drug active against CMV; but MUCH MORE nephrotoxic
  • Treatment of retinitis in HIV disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the 2 main mechanisms for resistance to anti-virals in Herpes Virus

A

• Two main mechanisms

  1. Thymidine Kinase mutants
    If occurs in TK, drugs not needing phosphorylation are still effective (e.g. foscarnet, cidofovir)
  2. DNA polymerase mutants
    If occurs in DNA polymerase, all drugs rendered less effective
    VERY RARE in immune competent patients (low viral load)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the types of HIV drugs?

A

Anti-reverse transcriptase inhibitors- nukes (nucleoside/nucleotide RT inhibitors- synthetic nucleoside thymidine analogue converted to di-nucleotide and then blocks RT by competing for substrate- dTTP- and incorporation into DNA by causing chain termination) and non-nukes (non-nucleotide RT inhibitors- allosteric. Non-competitive inhibitor of HIV-1 RT).

Protease inhibitors- multiple types

Integrase inhibitors – POL gene (protease, reverse transcriptase and integrase (IN) with the 3´end encoding for IN (polynucleotidyl transferase)).

Fusion inhibitors – gp120/41 - biomimetic lipopeptide.
Treatment - HAART- Combination of drugs to avoid resistance.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

When are PEPs taken?

When are PrEP taken?

A

PEP – within 72 hours post exposure -take for 28 days. 2x NRTIs + integrase inhibitor.

PrEP – pre-exposure - blocks transmission 2x NRTIs (Truvada). Two tablets 2 – 24 hours before sex, one 24 hours after sex and a further tablet 48 hours after sex - called ‘on-demand’ or ‘event based’ dosing.

2 x NRTIs = Combination of Nucleoside RTIs

Emtricitabine (guanosine analog) + tenofovir (adenosine analog).

17
Q

How can we develop resistance to HIV drugs?

What does resistance depend on?

What else can lead to viral variants?

A
  • Use of single agents leads to rapid development of resistance
  • The drug binding site is altered in structure by as few as one amino acid substitution
  • Mutation rate - high AND Viral load – high  resistance

Depends on selection pressure and mutation frequency. They form a quasispecies within an individual patient:- viral swarm.

Error rate for copying viral genome by RT and lack of proofreading over time will lead to all viral variants for HIV produced. Combination anti-virals needed, as a result- HAART.

18
Q

How does Amantadine and Zanamivir and Oseltamivir (Tamiflu) work against infleunza?

A

• Amantadine
o Inhibit virus uncoating by blocking the influenza encoded M2 protein when inside cells and assembly of haemagglutinin
o Now rarely used
o M2 acidifies the endosome which is required for fusing the membrane
• Zanamivir and Oseltamivir (Tamiflu)
o Inhibits virus release from infected cells via inhibition of neuraminidase
o Oseltamivir - oral
o Zanamivir- inhaled or IV - less likely for resistance to develop

19
Q

How can influenza develop resistance to anti-virals?

A
  • Resistance sometimes only requires a single amino acid change - seen recently with swine flu (H1N1) and Tamiflu (oseltamivir)
  • Point mutation (H275Y; tyrosine replacing histidine)
  • Seen in immunocompromised patients; shed virus for weeks/months
  • Likely to be selected from among quasispcies during treatment
  • Transmissible and virulent
  • Remains sensitive to zanamivir
20
Q

What are the occupational hazards to infection?

A
  • Exposure prone incidents - Sharps, Splashes and blood-born viruses
  • Prevention - Universal Precautions
  • Management -Emergency Management of exposure prone incidents
21
Q

Describe Post-exposure prophylaxis for HEP B, C and HIV

A

Hep B- specific Hep B immunoglobulin (passive immunity) + vaccination within 48 hours (HBV treatment includes antivirals 3TC/NRTIs).

Hep C- interferon- + ribavarin (anti-viral) for 6 months within first 2 months of exposure. 90% cure rate - now direct acting antivirals.

HIV- 80% protection i.e. no sero-conversion. Must be FAST – hours. Antiviral drug treatment – 28 days. 2xNRTI + protease or integrase inhibitor.

22
Q

Describe Hepatitis C virus (HCV)

A
  • Transmitted via blood – infectious (mother to baby)
  • Increasingly commo n – high risk groups – drug users 20% +ve; – needles (sex?)
  • Major cause of chronic liver disease
  • Estimated 170 million people infected worldwide
  • Occupational risk groups – healthcare workers
  • Needle-stick risk – 3% to sero-conversion; chronic carriage almost certain (85%)
  • Long incubation – 1 - 6 months
  • Vaccination not available
  • Prevalence in uk - ~6000 per year ( 95% are i/v drug users)
  • Early treatment facilitates resolution
23
Q

Describe Ribavirin

How does it work and what is it used to treat?

A
  • Nucleoside analogue
  • Block RNA synthesis by inhibiting inosine 5’-monophosphate (IMP) dehydrogenase this blocks the conversion of IMP to XMP (xanthosine 5’-monophosphate) and thereby stops GTP synthesis and, consequently, RNA synthesis
  • Treat: RSV and HepC (in combination with pegylated interferon)
  • Blocks the conversion of IMP to XMP
  • It has to be phosphorylated first in order to be active
  • Also useful for respiratory syncytial virus
24
Q

How do Direct acting antivirals (DAA) work?

A
  1. Relatively new class of medication.
  2. Acts to target specific steps in the HCV viral life cycle and shorten the length of therapy, minimize side effects, target the virus itself, improve sustained virologic response (SVR) rate.
  3. Structural and non-structural proteins - replicate and assemble new virions.
  4. HCV - first chronic viral infection to be cured without IFN or ribavirin.
  5. All the major HCV-induced enzymes - NS2-3 and NS3-4A proteases, NS3 helicase and NS5B RNA-dependent RNA polymerase (RdRp) are essential for HCV replication and are potential drug targets.
  6. DAA with different viral targets, are synergistic in combinations.
  7. Conclusion: Many viral infections with no effective therapies rabies, dengue, common cold viruses, Ebola, HPV, Arbovirsues.